Overview

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Status:
Withdrawn

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn about the safety and effectiveness of the combination of panobinostat, gemcitabine, busulfan, and melphalan, either with or without rituximab, in patients who have non-Hodgkin's or Hodgkin's lymphoma and are receiving a stem cell transplant.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

BB 1101
Busulfan
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Gemcitabine
Lenograstim
Melphalan
Panobinostat
Pyridoxal
Pyridoxine
Rituximab
Vitamin B 6